JAK2 mutations and coronary ischemia

New England Journal of Medicine

Volumn 363, Issue 4, 2010, Pages 396-397

  Lata, Kusum ^a   Madiraju, Nalini ^a   Levitt, Lee ^b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; JANUS KINASE 2;

ADULT; ASYSTOLE; CARDIOGENIC SHOCK; CASE REPORT; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG ELUTING STENT; GENE MUTATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT CORONARY ARTERY; LETTER; MALE; MICROTHROMBUS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STENT THROMBOSIS; THROMBOCYTHEMIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 77954825967     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1003478     Document Type: Letter

References (5)

1. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006;107:4214-22.
2. Hirshberg B, Shouval D, Fibach E, et al. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 2000;32:574-8. (Pubitemid 30180376)
3. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130:2031-8.
4. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-90.
5. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997;34:29-39. (Pubitemid 27063140)